...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Irinotecan Hydrochloride on Human Colorectal and Gastric Cancer Xenografts
【24h】

Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Irinotecan Hydrochloride on Human Colorectal and Gastric Cancer Xenografts

机译：新型口服化学治疗剂TAS-102与盐酸伊立替康联合化疗对人大肠癌和胃癌异种移植的疗效

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

TAS-102 is a novel oral nucleoside antitumor agent consisting of trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5. TAS-102 was approved in Japan in March 2014 for the treatment of patients with unresectable, advanced or recurrent colorectal cancer that is refractory to standard therapies. In the present study, enhancement of the therapeutic efficacy using a combination therapy of TAS-102 and irinotecan hydrochloride (CPT-11) was evaluated in a colorectal and gastric cancer xenograft-bearing nude mouse model. TAS-102 was orally administered twice a day from day 1 to 14, and CPT-11 was administered intravenously on days 1 and 8. The growth-inhibitory activity was evaluated based on the tumor volume and the growth-delay period, which was estimated based on the period required to reach a tumor volume that was five-times greater than the initial volume (RTV5). The tumor growth-inhibitory activity and the RTV5 of the group receiving TAS-102 with CPT-11 were significantly superior to those of both agents as monotherapy for mice with KM12C, KM12C/5-FU, DLD-1/5-FU, and SC-2 xenografts (p<0.01). No significant decrease in body weight was observed. The present pre-clinical findings indicated that the combination of TAS-102 and CPT-11 is a promising treatment option for colorectal or gastric cancer, not only for chemo-naive tumors, but also jar recurrent tumors after 5-fluorouracil (5-FU)-based chemotherapy.
机译：TAS-102是一种新型口服核苷类抗肿瘤药，由三氟吡啶和盐酸替吡西酯组成，摩尔比为1：0.5。 TAS-102于2014年3月在日本获得批准，可用于治疗无法切除，晚期或复发的大肠癌，这些患者对标准疗法均无效。在本研究中，在结直肠和胃癌异种移植裸鼠模型中评估了使用TAS-102和伊立替康盐酸盐（CPT-11）联合治疗的疗效。从第1天到第14天，每天口服两次TAS-102，在第1天和第8天，静脉内注射CPT-11。根据肿瘤的大小和生长延迟期评估其抑制生长的活性。取决于达到达到原始体积（RTV5）五倍的肿瘤体积所需的时间。对于使用KM12C，KM12C / 5-FU，DLD-1 / 5-FU和KM12C的小鼠，作为单一疗法，接受TAS-102和CPT-11的组的肿瘤生长抑制活性和RTV5明显优于两种药物。 SC-2异种移植物（p <0.01）。没有观察到体重显着降低。目前的临床前研究结果表明，TAS-102和CPT-11的结合是结直肠癌或胃癌的有前途的治疗选择，不仅适用于未经化学治疗的肿瘤，而且是5-氟尿嘧啶（5-FU ）为主的化疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号